Jieqiong Liu1, Ying Li2, Qian Li2, Dandan Liang3, Quanren Wang4, Qiang Liu5. 1. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Yanjiang West Road 107#, Guangzhou, 510120, China. liujq7@mail.sysu.edu.cn. 2. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Yanjiang West Road 107#, Guangzhou, 510120, China. 3. Genecast Precision Medicine Technology Institute, Beijing, China. 4. Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, Jiangsu, China. 5. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Yanjiang West Road 107#, Guangzhou, 510120, China. liuq77@mail.sysu.edu.cn.
Abstract
PURPOSE: We recently reported results of a phase II trial that camrelizumab plus apatinib induced an objective response rate (ORR) at 43.3% in advanced triple-negative breast cancer (TNBC). This study presents analysis of potential biomarkers. METHODS: TILs, CD8+ T cells and PD-1/PD-L1 expression were evaluated in tumor samples by immunohistochemistry. 59 Cytokines/chemokines, growth factors, or checkpoint-related proteins, blood immune cell subpopulations were analyzed in blood samples by multiplexed bead immunoassays or flow cytometry. Correlation between biomarkers and clinical outcomes including ORR, progression-free survival (PFS), and overall survival (OS) was analyzed. RESULTS: 28 Patients had biopsies and blood collected. Baseline TILs were significantly associated with longer PFS (P = 0.035). An increase of tumor-infiltrating CD8+ T cells > 15% during therapy was associated with higher ORR (P = 0.040). Patients with lower baseline plasma levels of HGF or IL-8 were more likely to respond to treatment (P = 0.005 or 0.001, respectively), and showed a longer PFS and OS. Patients with a decrease of IL-8, or an increase of TIM-3 or CD152 during treatment responded more to treatment (P = 0.008, 0.040, or 0.014, respectively). Responders had a higher baseline CD4+ T cells and B cell proportions in blood than non-responders (P = 0.002 and 0.030, respectively). CONCLUSION: Higher baseline TILs or a greater increase of tumor-infiltrating CD8+ T cells during therapy, lower baseline plasma HGF/IL-8, a decrease of plasma IL-8, an increase of plasma TIM-3/CD152 during therapy, higher baseline CD4+ T cells or B cells proportion in blood are potential biomarkers for combinational anti-angiogenesis and immunotherapy in advanced TNBC patients.
PURPOSE: We recently reported results of a phase II trial that camrelizumab plus apatinib induced an objective response rate (ORR) at 43.3% in advanced triple-negative breast cancer (TNBC). This study presents analysis of potential biomarkers. METHODS: TILs, CD8+ T cells and PD-1/PD-L1 expression were evaluated in tumor samples by immunohistochemistry. 59 Cytokines/chemokines, growth factors, or checkpoint-related proteins, blood immune cell subpopulations were analyzed in blood samples by multiplexed bead immunoassays or flow cytometry. Correlation between biomarkers and clinical outcomes including ORR, progression-free survival (PFS), and overall survival (OS) was analyzed. RESULTS: 28 Patients had biopsies and blood collected. Baseline TILs were significantly associated with longer PFS (P = 0.035). An increase of tumor-infiltrating CD8+ T cells > 15% during therapy was associated with higher ORR (P = 0.040). Patients with lower baseline plasma levels of HGF or IL-8 were more likely to respond to treatment (P = 0.005 or 0.001, respectively), and showed a longer PFS and OS. Patients with a decrease of IL-8, or an increase of TIM-3 or CD152 during treatment responded more to treatment (P = 0.008, 0.040, or 0.014, respectively). Responders had a higher baseline CD4+ T cells and B cell proportions in blood than non-responders (P = 0.002 and 0.030, respectively). CONCLUSION: Higher baseline TILs or a greater increase of tumor-infiltrating CD8+ T cells during therapy, lower baseline plasma HGF/IL-8, a decrease of plasma IL-8, an increase of plasma TIM-3/CD152 during therapy, higher baseline CD4+ T cells or B cells proportion in blood are potential biomarkers for combinational anti-angiogenesis and immunotherapy in advanced TNBC patients.
Entities:
Keywords:
Anti-angiogenesis; Biomarker analysis; PD-1 blockade; Triple-negative breast cancer
Authors: Xiaoxian Li; Jing Yang; Limin Peng; Aysegul A Sahin; Lei Huo; Kevin C Ward; Ruth O'Regan; Mylin A Torres; Jane L Meisel Journal: Breast Cancer Res Treat Date: 2016-11-25 Impact factor: 4.872
Authors: L Malorni; P B Shetty; C De Angelis; S Hilsenbeck; M F Rimawi; R Elledge; C K Osborne; S De Placido; G Arpino Journal: Breast Cancer Res Treat Date: 2012-11-04 Impact factor: 4.872
Authors: Otto Metzger-Filho; Zhuoxin Sun; Giuseppe Viale; Karen N Price; Diana Crivellari; Raymond D Snyder; Richard D Gelber; Monica Castiglione-Gertsch; Alan S Coates; Aron Goldhirsch; Fatima Cardoso Journal: J Clin Oncol Date: 2013-07-29 Impact factor: 44.544
Authors: Xuexin He; Jiali Ji; Rongrong Dong; Hong Liu; Xiaolan Dai; Chongjian Wang; Francisco J Esteva; Sai-Ching Jim Yeung Journal: Breast Cancer Res Treat Date: 2018-10-19 Impact factor: 4.872
Authors: Leisha A Emens; Cristina Cruz; Joseph Paul Eder; Fadi Braiteh; Cathie Chung; Sara M Tolaney; Irene Kuter; Rita Nanda; Philippe A Cassier; Jean-Pierre Delord; Michael S Gordon; Ehab ElGabry; Ching-Wei Chang; Indrani Sarkar; William Grossman; Carol O'Hear; Marcella Fassò; Luciana Molinero; Peter Schmid Journal: JAMA Oncol Date: 2019-01-01 Impact factor: 31.777